Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome Appearance After Lung Transplantation.
1CRTI UMR1064, INSERM, Université
de Nantes, ITUN, CHU Nantes, Nantes, France
2UMR_S 1087 CNRS UMR_6291, Institut du Thorax, Université
de Nantes, CHU de Nantes, Nantes, France
3CHU de Marseille, Aix Marseille Université, Marseille, France
4CHU de Strasbourg, Strasbourg, France
5Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardiopulmonaire, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France
6CHU de Bordeaux, Bordeaux, France
7Service de Pneumologie et Transplantation Pulmonaire, Hôpital Bichat, Paris, France
8Université
de Lyon, INRA, UMR754, Lyon, Hospices Civils de Lyon, Lyon, France
9Hôpital Européen George Pompidou, Paris, France
10CHU de Toulouse, Toulouse, France
11Hôpital Erasme, Bruxelles, Belgium
12Clinique Universitaire Pneumologie, Pôle Thorax et Vaisseaux, CHU de Grenoble, Université
de Grenoble, Inserm U1055, Grenoble, France
13Service de Pneumologie, Centre de Transplantation, Lausanne, Switzerland
Meeting: 2017 American Transplant Congress
Abstract number: D30
Keywords: Gene expression, Graft survival, Lung transplantation
Session Information
Session Name: Poster Session D: Diagnostics/Biomarkers Session II
Session Type: Poster Session
Date: Tuesday, May 2, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
Bronchiolitis obliterans syndrome (BOS) is the main manifestation of chronic lung allograft dysfunction responsible for the poor long-term outcome after lung transplantation. While physiopathological mechanisms are poorly defined, identification of harbingers of BOS is therefore essential to prevent the progression of the disease before irreversible damages appear. We performed gene expression analysis from peripheral whole blood of 80 lung transplanted recipients (LTR) using whole genome microarrays. Using an independent set of patients, including 13 LTR without and 11 with BOS 6 months before the clinical diagnosis, we identified differential genes between the two populations of patients that were validated by qPCR. Overall, 3 genes, POU Class 2 Associating Factor 1 (POU2AF1), T-cell leukemia/lymphoma protein 1A (TCL1A) and B-cell lymphocyte kinase (BLK), were identified as predictive biomarkers of BOS 6 months before the clinical diagnosis, with AUCs of 0.83, 0.77 and 0.78 respectively. These 3 genes allow stratifying upon CLAD risk (log-rank test p<0.01) and are not associated with time post-transplantation. These biomarkers could provide clinicians with new tools to adapt treatment and to improve long-term follow-up of LTR.
CITATION INFORMATION: Danger R, Royer P, Reboulleau D, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Kessler R, Mussot S, Dromer C, Brugière O, Mornex J, Guillemain R, Dahan M, Knoop C, Botturi K, Pison C, Nicod L, Brouard S, Magnan A, COLT and SysCLAD Consortia Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome Appearance After Lung Transplantation. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Danger R, Royer P, Reboulleau D, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Kessler R, Mussot S, Dromer C, Brugière O, Mornex J, Guillemain R, Dahan M, Knoop C, Botturi K, Pison C, Nicod L, Brouard S, Magnan A, Consortia COLTandSysCLAD. Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome Appearance After Lung Transplantation. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/blood-gene-expression-predicts-bronchiolitis-obliterans-syndrome-appearance-after-lung-transplantation/. Accessed November 22, 2024.« Back to 2017 American Transplant Congress